SUMMARY: Delayed-type hypersensitivity (DTH) responses against methylcholanthrene-induced fibrosarcomas in C3H/He and BDF1 mice were developed in BDF1 mice by sc injection of the respective mitomycin C-treated tumor cells. The DTH responses to the allogeneic and the syngeneic tumor cells were accelerated and enhanced tumor-specifically by priming 7 days previously with KCl extracts of the respective tumors. The ability in the mice primed with the tumor extracts enhancing the DTH response against the tumor cells could be transferred to recipient mice by the spleen cells, but not by the T-cell-depleted spleen cells.
INTRODUCTION
It is well known that the development of specific delayed-type hypersensitivity (DTH) to tumor antigens is correlated with the resistance to tumor growth in several transplantable tumors (Churchill et al., 1968; Halliday and Webb, 1968; Braum et al., 1978) . This fact suggests that the augmentation of specific DTH response to tumor antigens is effective to reinforce the resistance to tumor growth.
Previously, we demonstrated that an sc priming of mice 2 or more days previously with a low dose of SRBC or protein antigens resulted in an acceleration and enhancement of DTH response upon a subsequent application of the same antigen (Tamura and Egashira, 1976; Kojima, Tamura and Egashira, 1979) . We further demonstrated that priming of mice with the antigen induced (Fig.  4) . The tumor incidence also decreased in that order (Table  VI) . Thus, the resistance to syngeneic tumor growth seemed to have increased in parallel to the increase in the intensity of specific DTH response against the syngeneic tumor in immunized mice. These findings suggest that the induction of augmented DTH responses against tumor antigens may contribute to the reinforcement of the resistance to tumor growth in the transplantable tumor system. In the present experiments, we showed that memory T cells must be involved in the augmentation of tumor-specific DTH response (Tables IV and V) , which seemed to be related to the reinforcement of tumor immunity (Fig. 4, Table VI) , suggesting that the DTH-related memory T cells may play some role in the protection against tumors. We, however, have not obtained any direct evidence showing the role of DTH-related memory T cells or the roles of other cells involved in DTH response in the rejection of tumors. There seem to be several possible explanations concerning the significance of induction of specific DTH responses in the tumor rejection. One explanation is that some of lymphokines derived from the DTH-related, tumor-specific effector T cells may activate macrophages to kill tumor cells (Evans and Alexander, 1970 ). An alternative assumption is that effector cells for cytotoxic T lymphocyte (CTL) response involved in graft rejection (Cerottini and Brunner, 1974; MacDonald, Cerottini and Brunner, 1974; Delustro and Haskill, 1978) may be induced efficiently under the induction conditions of DTH-related cells. A third possibility is that helper T cells, which develop simultaneously with the induction of DTH-related memory T cells (Tamura and Egashira, 1976) , may be involved in the increased induction of CTL responses to reject tumors (Cantor and Boyse, 1975; Eyfe and Finke, 1979) . To solve these problems, it seems important to analyze the roles of memory T cells and of other cells involved in DTH response against tumor. Further studies on the roles of these cells in tumor rejection are currently in progress
